Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
- 6 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Gastric Cancer
- Vol. 24 (1), 60-71
- https://doi.org/10.1007/s10120-020-01094-0
Abstract
Background AT-rich interactive domain 1A (ARID1A) is a tumor suppressor gene that is frequently mutated in gastric cancer (GC). Although ARID1A mutations are not a druggable target for conventional treatments, novel therapeutic strategies based on a synthetic lethal approach are effective for ARID1A-deficient cancers. The histone methyltransferase EZH2 acts in a synthetic lethal manner in ARID1A-mutated ovarian cancer, although its role in GC remains unknown. Methods The selective sensitivity of the EZH2 inhibitors for ARID1A-deficient GC cells was evaluated using cell viability and colony formation assays. The expression of PI3K/AKT signaling genes were investigated using TCGA’s cBioPortal database to determine whether the homeostasis between ARID1A and EZH2 is related to cell proliferation and survival via the PI3K/AKT signaling pathway. We also evaluated the phosphorylation of PI3K/AKT signaling proteins in ARID1A knock downed ARID1A-WT GC cells. Results EZH2 inhibitors decreased the viability of ARID1A-deficient cells in a dose-dependent manner and demonstrated the selective sensitivity to ARID1A-deficient cells in vitro experiment system. Bioinformatics approach revealed that the PI3K/AKT signaling was tended to be activated in ARID1A-deficient GC enhancing cell viability and, furthermore, down-regulation of EZH2 in ARID1A-deficient GC was related to normalization of PI3K/AKT signaling pathway. The cell experiment revealed that phosphorylated AKT was upregulated in ARID1A-deficent GC cells. Conclusions The present findings provide a rationale for the selective sensitivity of EZH2 inhibitors against ARID1A-deficient GC and suggest the potential efficacy of targeted therapy using EZH2 inhibitors in this patient population.Keywords
Funding Information
- Japan Society for the Promotion of Science (18K08652, 19K09099)
This publication has 31 references indexed in Scilit:
- ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP InhibitorsCancer Discovery, 2015
- Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancersNature Medicine, 2015
- Comprehensive molecular characterization of gastric adenocarcinomaNature, 2014
- ARID1B is a specific vulnerability in ARID1A-mutant cancersNature Medicine, 2014
- OpenCFU, a New Free and Open-Source Software to Count Cell Colonies and Other Circular ObjectsPLOS ONE, 2013
- ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?Cancer Discovery, 2013
- Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferationProceedings of the National Academy of Sciences of the United States of America, 2012
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutationsNature, 2012
- A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsNature Chemical Biology, 2012
- Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancerNature Genetics, 2011